Around the Helix: Cell and Gene Therapy Company Updates – August 28, 2024 - CGTLive®
Cell and gene therapy sectors are rapidly advancing, with approvals, clinical trials, and new therapies emerging. Notable developments include Legend Biotech's Carvykti approval in China, JW Therapeutics' relma-cel approval for MCL, Galapagos' GLPG5101 IND clearance, CARsgen's satri-cel trial enrollment completion, Tome Biosciences' layoffs, Tern Therapeutics' launch with $15 million, Navigator Medicines' $100 million series A, and Borealis Biosciences' $150 million Series A funding.
Related Clinical Trials
Reference News
Cell and gene therapy sectors are rapidly advancing, with approvals, clinical trials, and new therapies emerging. Notable developments include Legend Biotech's Carvykti approval in China, JW Therapeutics' relma-cel approval for MCL, Galapagos' GLPG5101 IND clearance, CARsgen's satri-cel trial enrollment completion, Tome Biosciences' layoffs, Tern Therapeutics' launch with $15 million, Navigator Medicines' $100 million series A, and Borealis Biosciences' $150 million Series A funding.